The latest results for BioLineRx‘s new-generation antipsychotic BL-1020 for the treatment of schizophrenia show a reversal of cognitive impairment with minimal side effects and greater tolerability.

BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. It has recently completed a Phase IIb clinical trial, designed to assess performance in two distinct cognitive domains.

Recent pre-clinical studies show that BL-1020 reverses cognitive impairment and that this reversal is mediated by the GABA moiety of BL-1020.

BioLineRx CEO Morris Laster said that these results are extremely important for the confirmation of the mode of action of BL-1020 in reducing EPS and improving cognition.

“These results showing improved cognition may also allow for increased indication coverage for BL-1020 including dementia associated with Parkinson’s and even as a potential adjunct treatment for Alzheimer’s,” Laster said.